Corticosteroid weaning in the tacrolimus and mycophenolate era in heart transplantation: Clinical neurohormonal benefits

Transplantation Proceedings

Volumn 36, Issue 10, 2004, Pages 3152-3155

  Mehra, Mandeep R ^a,b   Uber, P A ^a   Park, M H ^a   Ventura, H O ^a   Scott, R L ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b Cardiomyopathy and Heart Transplantation Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CORTICOSTEROID; CYCLOSPORIN; LIPID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; CAUCASIAN; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; IMMUNOLOGY; MIDDLE AGED; NEGRO; PHYSIOLOGY; UNITED STATES;

ADRENAL CORTEX HORMONES; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LOUISIANA; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 21244500992     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.11.089     Document Type: Article

References (8)

1. Olivari MT, Jessen ME, Baldwin BJ, et al: Triple-drug immunosuppression with steroid discontinuation by six months after heart transplantation. J Heart Lung Transplant 14:127, 1995
2. Kobashigawa JA, Stevenson LW, Brownfield ED, et al: Corticosteroid weaning late after heart transplantation: relation to HLA-DR mismatching and long-term metabolic benefits. J Heart Lung Transplant 14:963, 1995
3. Taylor DO, Barr ML, Radovancevic B, et al: A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 18:336, 1999
4. Mehra MR, Uber PA, Park MH, Scott RL: Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil based immunosuppression. Transplantation 74:1568, 2002
5. Taylor DO, Bristow MR, O'Connell JB, et al: Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy. J Heart Lung Transplant 15:1039, 1996
6. Baran DA, Segura L, Kushwaha S, et al: Tacrolimus monotherapy in adult cardiac transplant recipients: intermediate-term results. J Heart Lung Transplant 20:59, 2001
7. Park MH, Scott RL, Uber PA, et al: Usefulness of B-type natriuretic peptide levels in predicting hemodynamic perturbations after heart transplantation despite preserved left ventricular systolic function. Am J Cardiol 90:1326, 2002
8. Uber PA, Mehra MR, Harris B, et al: Steroid weaning in heart transplantation is associated with decreased B-type natriuretic peptide: Surrogate evidence for cardiac adaptation. Transplant Proc 34:1843, 2002